Passage Bio holders approve Remix merger proposals
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Passage Bio stockholders approved merger-related proposals with Remix on November 5, 2026; the mergers remain pending and are expected to close in the fourth quarter of 2026, subject to Nasdaq listing application approval and customary procedures. For the nine months ended September 30, 2026, Remix’s unaudited results show collaboration revenue of $46.164 million, versus $2.509 million in 2025 and net loss of $14.438 million, versus $55.167 million. Revenue included $36.8 million recognized after the Janssen collaboration ended in August 2026; Remix expects no further revenue under it. Cash and equivalents were $29.264 million at September 30, 2026.
Remix received $100.0 million in gross concurrent-financing proceeds, including $70.0 million under the subscription agreement by November 17, 2026. It is expected to receive $10.7 million net cash from Passage Bio at closing. Remix concluded substantial doubt remains about its ability to continue as a going concern: the $70.0 million subscription proceeds depend on closing and must be returned if the mergers do not close. Pro forma information uses assumptions and estimates and is not actual or indicative of future combined-company results.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointRemix collaboration revenue rose to $46.164 million from $2.509 million for the nine months ended September 30, 2026, and 2025, respectively; $36.8 million was recognized under the Janssen agreement.
- Moderate pointRemix’s net loss narrowed to $14.438 million from $55.167 million for the nine months ended September 30, 2026, compared with 2025.
- Moderate pointRemix’s net cash used in operating activities declined to $38.923 million from $52.875 million for the nine months ended September 30, 2026, compared with 2025.
Negative
- Major pointRemix concluded substantial doubt remains about its ability to continue as a going concern; the $70.0 million in subscription proceeds must be returned if the mergers do not close. 6× market cap
Filing Explained
With the mergers still pending, the interim statements add a cash-use figure for Remix: it used
8-K Event Classification
Key Figures
Key Terms
going concern financial
pre-funded warrants financial
cost-to-cost input method financial
Level 3 liabilities financial
accounting acquirer financial
two-class method financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the status of PASG’s merger with Remix?
How much concurrent financing did Remix receive?
Why does Remix report substantial doubt about its ability to continue as a going concern?
Why did Remix terminate its Janssen collaboration?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
Address Not Applicable1
|
ZIP Code Not Applicable
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
|
|
Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
|
|
Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
|
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
|
Item 8.01
|
Other Events.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Unaudited Condensed Interim Financial Statements of Remix Therapeutics, Inc. as of and for the nine months ended September 30, 2026 and 2025.
|
|
99.2
|
Unaudited Pro Forma Combined Condensed Financial Information of Passage Bio, Inc., Remix Therapeutics, Inc., and the combined company resulting from the Mergers as of and for the
nine months ended September 30, 2026, and the year ended December 31, 2025.
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
PASSAGE BIO, INC.
|
||
|
Date: November 19, 2026
|
By:
|
/s/ Kathleen Borthwick
|
|
Kathleen Borthwick
|
||
|
Chief Financial Officer
|
||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
29,264
|
$
|
24,147
|
||||
|
Prepaid expenses and other current assets
|
5,527
|
1,208
|
||||||
|
Total current assets
|
34,791
|
25,355
|
||||||
|
Restricted cash
|
2,366
|
2,029
|
||||||
|
Operating lease right-of-use assets
|
14,075
|
14,959
|
||||||
|
Property and equipment, net
|
10,261
|
12,595
|
||||||
|
Other non-current assets
|
1,160
|
1,431
|
||||||
|
Total assets
|
$
|
62,653
|
$
|
56,369
|
||||
|
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
8,937
|
$
|
3,383
|
||||
|
Accrued expenses and other current liabilities
|
7,416
|
3,707
|
||||||
|
Operating lease liability, current portion
|
2,320
|
1,682
|
||||||
|
Deferred revenue, current portion
|
10,226
|
14,464
|
||||||
|
2026 Notes payable (includes $16,053 and $0 from related parties)
|
30,100
|
—
|
||||||
|
Total current liabilities
|
58,999
|
23,236
|
||||||
|
2025 Notes payable, related party
|
38,500
|
13,100
|
||||||
|
2023 Warrants and Letter Warrant liability (includes $345 and $6,170 from related parties)
|
354
|
6,286
|
||||||
|
2025 Warrant liability, related party
|
1,600
|
1,388
|
||||||
|
Pre-funded warrant liability, Series Seed convertible preferred stock
|
14,041
|
—
|
||||||
|
Pre-funded warrant liability, Series A convertible preferred stock
|
35,856
|
—
|
||||||
|
Pre-funded warrant liability, Series B convertible preferred stock
|
66,233
|
—
|
||||||
|
Contingent tranche liability, related party
|
—
|
500
|
||||||
|
Operating lease liability, net of current portion
|
19,947
|
21,736
|
||||||
|
Deferred revenue, net of current portion
|
26,217
|
60,143
|
||||||
|
Total liabilities
|
261,747
|
126,389
|
||||||
|
Commitments and contingencies (Note 16)
|
||||||||
|
Convertible preferred stock (Series Seed, A and B), $0.0001 par value;
124,133,326 shares authorized at both September 30, 2026
and December 31, 2025; 33,026,156 and 118,136,265 shares issued and
outstanding at September 30, 2026 and December 31, 2025,
respectively; aggregate liquidation preference of $58,557 and
$219,390 at September 30, 2026 and December 31, 2025, respectively
|
53,765
|
200,865
|
||||||
|
Stockholders’ deficit:
|
||||||||
|
Common stock, $0.0001 par value; 162,000,000 shares authorized at both September 30, 2026 and
December 31, 2025; 5,201,899 and 7,811,834 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
|
1
|
1
|
||||||
|
Additional paid-in capital
|
53,574
|
21,110
|
||||||
|
Accumulated deficit
|
(306,434
|
)
|
(291,996
|
)
|
||||
|
Total stockholders’ deficit
|
(252,859
|
)
|
(270,885
|
)
|
||||
|
Total liabilities, convertible preferred stock and stockholders’ deficit
|
$
|
62,653
|
$
|
56,369
|
||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Collaboration revenue
|
$
|
46,164
|
$
|
2,509
|
||||
|
Operating expenses:
|
||||||||
|
Research and development
|
40,880
|
43,474
|
||||||
|
General and administrative
|
15,894
|
11,899
|
||||||
|
Total operating expenses
|
56,774
|
55,373
|
||||||
|
Loss from operations
|
(10,610
|
)
|
(52,864
|
)
|
||||
|
Other (expense) income:
|
||||||||
|
Change in fair value of convertible notes payable, warrant liabilities and contingent tranche
liability, related party
|
(4,280
|
)
|
(3,580
|
)
|
||||
|
Interest income
|
473
|
1,127
|
||||||
|
Other expense, net
|
(21
|
)
|
(24
|
)
|
||||
|
Total other expense, net
|
(3,828
|
)
|
(2,477
|
)
|
||||
|
Loss before income taxes
|
(14,438
|
)
|
(55,341
|
)
|
||||
|
Income tax expense (benefit)
|
—
|
(174
|
)
|
|||||
|
Net loss and comprehensive loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Deemed contribution related to preferred stock exchange
|
30,970
|
—
|
||||||
|
Less: Earnings allocated to participating preferred securities
|
(16,319
|
)
|
—
|
|||||
|
Net income (loss) attributable to common stockholders
|
$
|
213
|
$
|
(55,167
|
)
|
|||
|
Weighted-average common shares outstanding — basic
|
7,918,093
|
7,689,038
|
||||||
|
Weighted-average common shares outstanding — diluted
|
51,127,610
|
7,689,038
|
||||||
|
Net income (loss) per share of common stock — basic
|
$
|
0.03
|
$
|
(7.17
|
)
|
|||
|
Net income (loss) per share of common stock — diluted
|
$
|
(0.42
|
)
|
$
|
(7.17
|
)
|
||
|
Series Seed, A and B
Convertible Preferred Stock
|
Common Stock
|
Additional
|
Accumulated
|
Total
Stockholders’
|
||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Deficit
|
||||||||||||||||||||||
|
Balance at December 31, 2024
|
87,203,974
|
$
|
132,793
|
7,626,774
|
$
|
1
|
$
|
18,818
|
$
|
(218,291
|
)
|
$
|
(199,472
|
)
|
||||||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
—
|
(55,167
|
)
|
(55,167
|
)
|
|||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
—
|
—
|
1,714
|
—
|
1,714
|
|||||||||||||||||||||
|
Exercise of stock options
|
—
|
—
|
88,220
|
—
|
49
|
—
|
49
|
|||||||||||||||||||||
|
Balance at September 30, 2025
|
87,203,974
|
$
|
132,793
|
7,714,994
|
$
|
1
|
$
|
20,581
|
$
|
(273,458
|
)
|
$
|
(252,876
|
)
|
||||||||||||||
|
Balance at December 31, 2025
|
118,136,265
|
$
|
200,865
|
7,811,834
|
$
|
1
|
$
|
21,110
|
$
|
(291,996
|
)
|
$
|
(270,885
|
)
|
||||||||||||||
|
Net loss
|
—
|
—
|
—
|
—
|
—
|
(14,438
|
)
|
(14,438
|
)
|
|||||||||||||||||||
|
Exchange of common stock for pre-funded warrants
|
—
|
—
|
(3,000,000
|
)
|
—
|
—
|
—
|
—
|
||||||||||||||||||||
|
Exchange of convertible preferred stock (Series Seed, A and B) for pre-funded warrants
|
(85,110,109
|
)
|
(147,100
|
)
|
—
|
—
|
30,970
|
—
|
30,970
|
|||||||||||||||||||
|
Stock-based compensation expense
|
—
|
—
|
—
|
—
|
1,237
|
—
|
1,237
|
|||||||||||||||||||||
|
Exercise of stock options
|
—
|
—
|
390,065
|
—
|
257
|
—
|
257
|
|||||||||||||||||||||
|
Balance at September 30, 2026
|
33,026,156
|
$
|
53,765
|
5,201,899
|
$
|
1
|
$
|
53,574
|
$
|
(306,434
|
)
|
$
|
(252,859
|
)
|
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization expense
|
2,049
|
2,390
|
||||||
|
Stock-based compensation expense
|
1,237
|
1,714
|
||||||
|
Change in fair value of convertible notes payable, warrant liabilities and
contingent tranche liability, related party
|
4,280
|
3,580
|
||||||
|
Amortization of deferred issuance costs
|
—
|
203
|
||||||
|
Loss on disposal and sale of property and equipment
|
244
|
5
|
||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
—
|
353
|
||||||
|
Prepaid expenses and other assets
|
(265
|
)
|
907
|
|||||
|
Accounts payable
|
3,201
|
(3,036
|
)
|
|||||
|
Accrued expenses and other current liabilities
|
3,199
|
(422
|
)
|
|||||
|
Operating lease liabilities
|
(266
|
)
|
(893
|
)
|
||||
|
Deferred revenue
|
(38,164
|
)
|
(2,509
|
)
|
||||
|
Net cash used in operating activities
|
(38,923
|
)
|
(52,875
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
(6
|
)
|
(42
|
)
|
||||
|
Proceeds from sales of property and equipment
|
54
|
—
|
||||||
|
Net cash provided by (used in) investing activities
|
48
|
(42
|
)
|
|||||
|
Cash flows from financing activities:
|
||||||||
|
Payment of deferred issuance costs
|
(286
|
)
|
—
|
|||||
|
Issuance costs for convertible promissory note
|
(642
|
)
|
—
|
|||||
|
Proceeds from issuance of convertible notes payable
|
45,000
|
—
|
||||||
|
Proceeds from exercise of stock options
|
257
|
49
|
||||||
|
Net cash provided by financing activities
|
44,329
|
49
|
||||||
|
Net increase (decrease) in cash, cash equivalents and restricted cash
|
5,454
|
(52,868
|
)
|
|||||
|
Cash, cash equivalents and restricted cash, beginning of period
|
26,176
|
75,522
|
||||||
|
Cash, cash equivalents and restricted cash, end of period
|
$
|
31,630
|
$
|
22,654
|
||||
|
Supplemental disclosures of non-cash information:
|
||||||||
|
Offering costs accrued but not yet paid
|
$
|
3,506
|
$
|
—
|
||||
|
Exchange of common stock and convertible preferred stock for pre-funded warrants (see Note 1)
|
116,130
|
—
|
||||||
|
September 30, 2026
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
24,395
|
$
|
—
|
$
|
—
|
$
|
24,395
|
||||||||
|
$
|
24,395
|
$
|
—
|
$
|
—
|
$
|
24,395
|
|||||||||
|
Liabilities:
|
||||||||||||||||
|
2026 Notes payable
|
$
|
—
|
$
|
—
|
$
|
30,100
|
$
|
30,100
|
||||||||
|
2025 Notes payable
|
—
|
—
|
38,500
|
38,500
|
||||||||||||
|
2023 Warrant liability*
|
—
|
—
|
354
|
354
|
||||||||||||
|
2025 Warrant liability
|
—
|
—
|
1,600
|
1,600
|
||||||||||||
|
Pre-funded warrant liability, Series Seed convertible preferred stock
|
—
|
—
|
14,041
|
14,041
|
||||||||||||
|
Pre-funded warrant liability, Series A convertible preferred stock
|
—
|
—
|
35,856
|
35,856
|
||||||||||||
|
Pre-funded warrant liability, Series B convertible preferred stock
|
—
|
—
|
66,233
|
66,233
|
||||||||||||
|
$
|
—
|
$
|
—
|
$
|
186,684
|
$
|
186,684
|
|||||||||
|
*
|
The 2023 Warrant liability includes warrants issued to obtain a line of credit amounting to less than $0.1 million as of September 30,
2026.
|
|
December 31, 2025
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
15,433
|
$
|
—
|
$
|
—
|
$
|
15,433
|
||||||||
|
|
$
|
15,433
|
$
|
—
|
$
|
—
|
$
|
15,433
|
||||||||
|
Liabilities:
|
||||||||||||||||
|
2025 Notes payable
|
$
|
—
|
$
|
—
|
$
|
13,100
|
$
|
13,100
|
||||||||
|
2023 Warrant liability*
|
—
|
—
|
6,286
|
6,286
|
||||||||||||
|
2025 Warrant liability
|
—
|
—
|
1,388
|
1,388
|
||||||||||||
|
Contingent tranche liability
|
—
|
—
|
500
|
500
|
||||||||||||
|
|
$
|
—
|
$
|
—
|
$
|
21,274
|
$
|
21,274
|
||||||||
|
*
|
The 2023 Warrant liability includes warrants issued to obtain a line of credit amounting to $0.1 million as of December 31, 2025.
|
|
2026
Notes
payable
|
2025
Notes
payable
|
2023
Warrant
liability*
|
2025
Warrant
liability
|
Contingent
tranche liability
|
Pre-funded
warrant
liability,
Series Seed
convertible
preferred
stock
|
Pre-funded
warrant
liability,
Series A
convertible
preferred
stock
|
Pre-funded
warrant
liability,
Series B
convertible
preferred
stock
|
|||||||||||||||||||||||||
|
Balance at December 31, 2025
|
$
|
—
|
$
|
13,100
|
$
|
6,286
|
$
|
1,388
|
$
|
500
|
$
|
—
|
$
|
—
|
$
|
—
|
||||||||||||||||
|
Issuances
|
30,000
|
13,500
|
—
|
1,500
|
—
|
14,041
|
35,856
|
66,233
|
||||||||||||||||||||||||
|
Adjustments to estimated fair value
|
100
|
11,900
|
(5,932
|
)
|
(1,288
|
)
|
—
|
—
|
—
|
—
|
||||||||||||||||||||||
|
Settlements
|
—
|
—
|
—
|
—
|
(500
|
)
|
—
|
—
|
—
|
|||||||||||||||||||||||
|
Balance at September 30, 2026
|
$
|
30,100
|
$
|
38,500
|
$
|
354
|
$
|
1,600
|
$
|
—
|
$
|
14,041
|
$
|
35,856
|
$
|
66,233
|
||||||||||||||||
|
2025 Notes payable
|
2023 Warrant
liability*
|
|||||||
|
Balance at December 31, 2024
|
$
|
59,600
|
$
|
4,136
|
||||
|
Adjustments to estimated fair value
|
4,300
|
(720
|
)
|
|||||
|
Balance at September 30, 2025
|
$
|
63,900
|
$
|
3,416
|
||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Risk-free interest rate
|
3.90% - 4.40%
|
|
3.62% - 3.90%
|
|
||||
|
Expected dividend rate
|
0.00%
|
|
0.00%
|
|
||||
|
Expected stock price volatility
|
77.00% - 91.00%
|
|
48.00% - 94.00%
|
|
||||
|
Expected term (years)
|
0.16 - 1.83
|
0.25 - 2.00
|
||||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Risk-free interest rate
|
3.90% - 4.40%
|
|
3.60% - 3.70%
|
|
||||
|
Expected dividend rate
|
0.00%
|
|
0.00%
|
|
||||
|
Expected stock price volatility
|
61.00% - 105.9%
|
|
85.90% - 95.00%
|
|
||||
|
Expected term (years)
|
0.16 - 1.83
|
1.00 - 2.00
|
||||||
|
September 30,
2026
|
December 31,
2025
|
September 30,
2025
|
December 31,
2024
|
|||||||||||||
|
Cash and cash equivalents
|
$
|
29,264
|
$
|
24,147
|
$
|
20,632
|
$
|
73,424
|
||||||||
|
Restricted cash
|
2,366
|
2,029
|
2,022
|
2,098
|
||||||||||||
|
$
|
31,630
|
$
|
26,176
|
$
|
22,654
|
$
|
75,522
|
|||||||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Leasehold improvements
|
$
|
14,100
|
$
|
14,100
|
||||
|
Laboratory equipment
|
7,233
|
7,523
|
||||||
|
Furniture and fixtures
|
798
|
798
|
||||||
|
Computer equipment and software
|
250
|
250
|
||||||
|
22,381
|
22,671
|
|||||||
|
Less: Accumulated depreciation and amortization
|
(12,120
|
)
|
(10,076
|
)
|
||||
|
$
|
10,261
|
$
|
12,595
|
|||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Prepaid expenses and other current assets
|
$
|
1,735
|
$
|
1,208
|
||||
|
Deferred issuance costs
|
3,792
|
-
|
||||||
|
$
|
5,527
|
$
|
1,208
|
|||||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Accrued research and development costs
|
$
|
4,201
|
$
|
1,862
|
||||
|
Accrued employee compensation and benefits
|
2,006
|
1,414
|
||||||
|
Accrued professional services and other
|
1,209
|
431
|
||||||
|
$
|
7,416
|
$
|
3,707
|
|||||
|
September 30, 2026
|
||||||||||||||||||||
|
Shares
Authorized
|
Shares
Issued and
Outstanding
|
Carrying
Value
|
Liquidation
Preference
|
Common Stock
Issuable Upon
Conversion
|
||||||||||||||||
|
Series Seed Preferred Stock
|
17,964,705
|
7,564,454
|
$
|
7,032
|
$
|
7,158
|
7,564,454
|
|||||||||||||
|
Series A Preferred Stock
|
35,714,365
|
9,296,900
|
15,083
|
17,647
|
9,296,900
|
|||||||||||||||
|
Series B Preferred Stock
|
70,454,256
|
16,164,802
|
31,650
|
33,752
|
16,164,802
|
|||||||||||||||
|
124,133,326
|
33,026,156
|
$
|
53,765
|
$
|
58,557
|
33,026,156
|
||||||||||||||
|
December 31, 2025
|
||||||||||||||||||||
|
Shares
Authorized
|
Shares
Issued and
Outstanding
|
Carrying
Value
|
Liquidation
Preference
|
Common Stock
Issuable Upon
Conversion
|
||||||||||||||||
|
Series Seed Preferred Stock
|
17,964,705
|
17,964,705
|
$
|
16,700
|
$
|
17,000
|
17,964,705
|
|||||||||||||
|
Series A Preferred Stock
|
35,714,365
|
35,661,683
|
57,856
|
67,693
|
35,661,683
|
|||||||||||||||
|
Series B Preferred Stock
|
70,454,256
|
64,509,877
|
126,309
|
134,697
|
64,509,877
|
|||||||||||||||
|
124,133,326
|
118,136,265
|
$
|
200,865
|
$
|
219,390
|
118,136,265
|
||||||||||||||
|
Shares Exchanged
|
||||
|
Series Seed Preferred Stock
|
10,400,251
|
|||
|
Series A Preferred Stock
|
26,364,783
|
|||
|
Series B Preferred Stock
|
48,345,075
|
|||
|
Total
|
85,110,109
|
|||
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
Shares reserved for the conversion of authorized Series Seed
Preferred Stock
|
17,964,705
|
17,964,705
|
||||||
|
Shares reserved for the conversion of authorized Series A Preferred Stock
|
35,714,365
|
35,714,365
|
||||||
|
Shares reserved for the conversion of authorized Series B Preferred Stock*
|
70,454,256
|
70,454,256
|
||||||
|
Common shares reserved for exercise of pre-funded warrants
|
3,000,000
|
-
|
||||||
|
Common stock options available for grant under the 2019 Plan
|
1,720,290
|
4,553,047
|
||||||
|
Common stock options outstanding under the 2019 Plan
|
19,371,301
|
16,928,609
|
||||||
|
148,224,917
|
145,614,982
|
|||||||
|
*
|
Includes shares of 2023 Warrants and Letter Warrants at both September 30, 2026 and December 31, 2025.
|
|
Number
of Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Life
|
Aggregate
Intrinsic
Value
|
|||||||||||||
|
(in years)
|
(in thousands)
|
|||||||||||||||
|
Outstanding at December 31, 2025
|
16,928,609
|
$
|
0.75
|
5.94
|
$
|
7,179
|
||||||||||
|
Granted
|
5,378,960
|
$
|
1.15
|
|||||||||||||
|
Exercised
|
(390,065
|
)
|
$
|
0.66
|
||||||||||||
|
Forfeited or canceled
|
(2,546,203
|
)
|
$
|
0.80
|
||||||||||||
|
Outstanding at September 30, 2026
|
19,371,301
|
$
|
0.85
|
6.98
|
$
|
5,420
|
||||||||||
|
|
||||||||||||||||
|
Vested and expected to vest at September 30, 2026
|
18,879,278
|
$
|
0.84
|
6.94
|
$
|
5,420
|
||||||||||
|
Exercisable at September 30, 2026
|
12,370,156
|
$
|
0.69
|
5.71
|
$
|
5,301
|
||||||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
General and administrative expense
|
$
|
505
|
$
|
1,054
|
||||
|
Research and development expense
|
732
|
660
|
||||||
|
$
|
1,237
|
$
|
1,714
|
|||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Numerator:
|
||||||||
|
Net loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
|
Deemed dividend on exchange of Series Seed convertible preferred stock
|
(4,372
|
)
|
—
|
|||||
|
Deemed contributions on exchange of Series A and Series B convertible preferred stock
|
35,342
|
—
|
||||||
|
Net income (loss) attributable to common shareholders and participating securities
|
$
|
16,532
|
$
|
(55,167
|
)
|
|||
|
Less: 8% noncumulative dividend preference allocated to participating securities
|
(13,127
|
)
|
—
|
|||||
|
Less: remaining undistributed earnings allocated to participating securities
|
(3,192
|
)
|
—
|
|||||
|
Net income (loss) allocated to common stockholders, basic
|
$
|
213
|
$
|
(55,167
|
)
|
|||
|
Add: undistributed earnings allocated to Series B convertible preferred stock exchanged under the
Exchange Agreements
|
6,566
|
—
|
||||||
|
Less: reversal of deemed contribution on Series B convertible preferred stock exchanged under the
Exchange Agreements
|
(28,426
|
)
|
—
|
|||||
|
Net income (loss) attributable to common stockholders, diluted
|
$
|
(21,647
|
)
|
$
|
(55,167
|
)
|
||
|
Denominator:
|
||||||||
|
Weighted-average common shares outstanding, basic
|
7,918,093
|
7,689,038
|
||||||
|
Add: Series B convertible preferred stock exchanged under the Exchange Agreements, as converted
|
43,209,517
|
—
|
||||||
|
Weighted-average common shares outstanding, diluted
|
51,127,610
|
7,689,038
|
||||||
|
Net income (loss) per share attributable to common stockholders, basic
|
$
|
0.03
|
$
|
(7.17
|
)
|
|||
|
Net income (loss) per share attributable to common stockholders, diluted
|
$
|
(0.42
|
)
|
$
|
(7.17
|
)
|
||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Convertible preferred stock (as converted to common stock)
|
33,026,156
|
87,203,974
|
||||||
|
Stock options to purchase common stock
|
19,371,301
|
17,688,691
|
||||||
|
Pre-funded warrants to purchase convertible preferred stock
|
85,110,109
|
—
|
||||||
|
Warrants issued in relation to a line of credit
|
143,549
|
143,549
|
||||||
|
Warrants issued in relation to 2023 convertible promissory notes payable
|
5,753,715
|
—
|
||||||
|
Nine Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Collaboration revenue
|
$
|
46,164
|
$
|
2,509
|
||||
|
Research and development expenses:
|
||||||||
|
Personnel costs
|
7,582
|
11,342
|
||||||
|
MYB program
|
23,206
|
16,241
|
||||||
|
Other preclinical programs
|
4,311
|
8,821
|
||||||
|
Facilities, laboratory supplies and other
|
5,781
|
7,070
|
||||||
|
General and administrative expenses:
|
||||||||
|
Personnel costs
|
4,019
|
4,605
|
||||||
|
Facilities, laboratory supplies and other
|
11,875
|
7,294
|
||||||
|
Other segment items*
|
3,828
|
2,303
|
||||||
|
Net loss and comprehensive loss
|
$
|
(14,438
|
)
|
$
|
(55,167
|
)
|
||
| (i) |
to the extent not exchanged pursuant to the Exchange Agreements, outstanding Remix convertible notes,including the 2026 Bridge Notes, will convert into shares of Remix common
stock in accordance with their terms, and
|
| (ii) |
to the extent not exchanged pursuant to the Exchange Agreements, outstanding Remix preferred stock will convert into shares of Remix common stock pursuant to the organizational
documents of Remix (the‘‘Remix Preferred Stock Conversion’’).
|
| (i) |
each outstanding share of Remix common stock, other than shares issued in the Concurrent Financing, dissenting shares, treasury shares and shares previously exchanged under the
Exchange Agreements, will convert into the right to receive Passage Bio common stock, par value $0.0001 per share (“Passage Bio Common Stock”), at the Merger Exchange Ratio of approximately 0.0289,
|
| (ii) |
each share of Remix common stock issued in the Concurrent Financing, including shares resulting from conversion of the 2026 Bridge Notes, will convert into the right to receive
Passage Bio Common Stock at the Concurrent Financing Exchange Ratio of approximately 0.0291;
|
| (iii) |
each then-outstanding and unexercised option to purchase Remix common stock will be assumed by Passage Bio and become an option to acquire Passage Bio Common Stock, with the
applicable adjustments to the number of shares and exercise price, and
|
| (iv) |
each then-outstanding Remix pre-funded warrant, including a pre-funded warrant issued pursuant to an Exchange Agreement or the Subscription Financing, will be assumed and
converted into a pre-funded warrant to purchase Passage Bio Common Stock, applying the appropriate exchange ratio and exercise-price adjustment.
|
| • |
The 2023 Warrants will terminate in accordance with their terms. The liability associated with the 2023 Warrants and Letter Warrant will be derecognized in connection with the
Mergers (see Adjustment G).
|
| • |
Certain of the 2025 Warrants, which are exercisable at 80% of the Subscription Financing price (approximately $1.11), will be surrendered and exchanged pursuant to the Exchange
Agreements for pre-funded warrants to purchase Remix common stock. The remaining 2025 Warrants will be net exercised for shares of Remix common stock, which will be converted into Passage Bio Common Stock in the Mergers.
|
| • |
The Letter Warrant will be assumed by Passage Bio and will convert into a warrant to purchase Passage Bio Common Stock.
|
| • |
The pre-funded warrants will be issued pursuant to the Exchange Agreements and Subscription Financing will become exercisable for shares of Passage Bio Common Stock based on
the applicable exchange ratios.
|
|
Shares
|
%
|
|||||||
|
Remix historical shareholders (i)
|
4,526,259
|
63.0
|
%
|
|||||
|
Investors in Concurrent Financing (ii)
|
2,116,032
|
29.5
|
%
|
|||||
|
Passage Bio historical shareholders
|
538,802
|
7.5
|
%
|
|||||
|
Estimated total shares of Passage Bio Common Stock
|
7,181,093
|
100.0
|
%
|
|||||
| (i) |
Includes 3,156,410 Passage Bio Pre-Funded Warrants expected to be issued in exchange for Remix Pre-funded warrants.
|
| (ii) |
Includes 940,799 Passage Bio pre-funded warrants expected to be issued in the Concurrent Financing.
|
| • |
the historical unaudited interim financial statements of Remix as of and for the nine months ended September 30, 2026, the historical audited financial statements of Remix as
of and for the year ended December 31, 2025, and the related notes included in this Current Report on Form 8-K or the proxy statement/prospectus filed with the SEC on October 9, 2026 pursuant to Rule 424(b)(3) (the “proxy
statement/prospectus”);
|
| • |
the historical unaudited interim financial statements of Passage Bio as of and for the nine months ended September 30, 2026, the historical audited financial statements of
Passage Bio as of and for the year ended December 31, 2025, and the related notes included in its periodic reports or the proxy statement/prospectus.
|
|
|
As of September 30,
2026
|
|||||||||||||||||||||||||
|
|
Historical
|
Transaction Accounting
Adjustments
|
||||||||||||||||||||||||
|
|
Remix
|
Passage
|
Merger
Adjustments
|
Financing
Adjustments
|
Pro
Forma
Combined
|
|||||||||||||||||||||
|
|
||||||||||||||||||||||||||
|
Assets
|
||||||||||||||||||||||||||
|
Current assets:
|
||||||||||||||||||||||||||
|
Cash and cash equivalents
|
$
|
29,264
|
$
|
20,160
|
$
|
(2,046
|
)
|
B
|
$
|
65,226
|
A
|
$
|
96,893
|
|||||||||||||
|
|
(10,587
|
)
|
D
|
|||||||||||||||||||||||
|
|
(5,124
|
)
|
C
|
|||||||||||||||||||||||
|
Prepaid expenses and other current assets
|
5,527
|
517
|
1,000
|
D
|
(3,792
|
)
|
A
|
3,252
|
||||||||||||||||||
|
Prepaid research and development
|
116
|
-
|
-
|
116
|
||||||||||||||||||||||
|
Total current assets
|
34,791
|
20,793
|
(16,757
|
)
|
61,434
|
100,261
|
||||||||||||||||||||
|
Restricted cash
|
2,366
|
-
|
-
|
2,366
|
||||||||||||||||||||||
|
Operating lease right-of-use assets
|
14,075
|
-
|
-
|
14,075
|
||||||||||||||||||||||
|
Property and equipment, net
|
10,261
|
-
|
-
|
10,261
|
||||||||||||||||||||||
|
Other non-current assets
|
1,160
|
-
|
-
|
1,160
|
||||||||||||||||||||||
|
Total assets
|
$
|
62,653
|
$
|
20,793
|
$
|
(16,757
|
)
|
$
|
61,434
|
$
|
128,123
|
|||||||||||||||
|
|
||||||||||||||||||||||||||
|
Liabilities, Convertible Preferred Stock and Stockholders’ (Deficit) Equity
|
||||||||||||||||||||||||||
|
Current liabilities:
|
||||||||||||||||||||||||||
|
Accounts payable
|
$
|
8,937
|
$
|
533
|
$
|
(594
|
)
|
B
|
$
|
(3,297
|
)
|
A
|
$
|
5,579
|
||||||||||||
|
Accrued expenses and other current liabilities
|
7,416
|
3,183
|
-
|
(495
|
)
|
A
|
10,104
|
|||||||||||||||||||
|
Operating lease liability, current portion
|
2,320
|
-
|
-
|
2,320
|
||||||||||||||||||||||
|
Non-refundable sublicense and transition services payment
|
-
|
17,027
|
(17,027
|
)
|
E
|
-
|
-
|
|||||||||||||||||||
|
Deferred revenue, current portion
|
10,226
|
10,226
|
||||||||||||||||||||||||
|
2026 Notes payable (includes $16,053 from related parties)
|
30,100
|
(30,100
|
)
|
B
|
-
|
|||||||||||||||||||||
|
Total current liabilities
|
58,999
|
20,743
|
(47,721
|
)
|
(3,792
|
)
|
28,229
|
|||||||||||||||||||
|
2025 Notes payable, related party
|
38,500
|
(38,500
|
)
|
F
|
-
|
-
|
||||||||||||||||||||
|
2023 Warrants and Letter Warrant liability (includes $345 and $6,170 from related parties)
|
354
|
(354
|
)
|
G
|
-
|
-
|
||||||||||||||||||||
|
2025 Warrant liability, related party
|
1,600
|
(1,600
|
)
|
H
|
-
|
-
|
||||||||||||||||||||
|
Prefunded warrant liability, Series Seed convertible preferred stock
|
14,041
|
(14,041
|
)
|
L
|
-
|
|||||||||||||||||||||
|
Prefunded warrant liability, Series A convertible preferred stock
|
35,856
|
(35,856
|
)
|
L
|
-
|
|||||||||||||||||||||
|
Prefunded warrant liability, Series B convertible preferred stock
|
66,233
|
(66,233
|
)
|
L
|
-
|
|||||||||||||||||||||
|
Operating lease liability, net of current portion
|
19,947
|
-
|
-
|
19,947
|
||||||||||||||||||||||
|
Deferred revenue, net of current portion
|
26,217
|
-
|
-
|
26,217
|
||||||||||||||||||||||
|
Total liabilities
|
261,747
|
20,743
|
(204,305
|
)
|
(3,792
|
)
|
74,393
|
|||||||||||||||||||
|
Commitments and contingencies
|
||||||||||||||||||||||||||
|
Convertible preferred stock
|
53,765
|
(53,765
|
)
|
I
|
-
|
-
|
||||||||||||||||||||
|
Stockholders’ (deficit) equity:
|
||||||||||||||||||||||||||
|
Common stock - historical
|
1
|
(1
|
)
|
I
|
-
|
|||||||||||||||||||||
|
Common stock - NewCo
|
-
|
B
|
-
|
A
|
-
|
|||||||||||||||||||||
|
|
-
|
F
|
||||||||||||||||||||||||
|
|
-
|
H
|
||||||||||||||||||||||||
|
|
-
|
I
|
||||||||||||||||||||||||
|
Additional paid-in capital - historical
|
53,574
|
724,906
|
(9,587
|
)
|
D
|
-
|
366,725
|
|||||||||||||||||||
|
|
||||||||||||||||||||||||||
|
Additional paid-in capital - NewCo
|
28,648
|
B
|
65,226
|
A
|
||||||||||||||||||||||
|
|
17,027
|
E
|
||||||||||||||||||||||||
|
|
38,500
|
F
|
||||||||||||||||||||||||
|
|
354
|
G
|
||||||||||||||||||||||||
|
|
53,766
|
I
|
||||||||||||||||||||||||
|
|
1,600
|
H
|
-
|
|||||||||||||||||||||||
|
|
(724,856
|
)
|
J
|
-
|
||||||||||||||||||||||
|
|
1,437
|
K
|
-
|
|||||||||||||||||||||||
|
|
14,041
|
L
|
||||||||||||||||||||||||
|
|
35,856
|
L
|
||||||||||||||||||||||||
|
|
66,233
|
L
|
||||||||||||||||||||||||
|
Accumulated deficit
|
(306,434
|
)
|
(724,856
|
)
|
(5,124
|
)
|
C
|
-
|
(312,995
|
)
|
||||||||||||||||
|
|
724,856
|
J
|
-
|
|||||||||||||||||||||||
|
|
(1,437
|
)
|
K
|
-
|
||||||||||||||||||||||
|
Total stockholders’ (deficit) equity
|
(252,859
|
)
|
50
|
241,313
|
65,226
|
53,730
|
||||||||||||||||||||
|
Total liabilities, convertible preferred stock and stockholders’ (deficit) equity
|
$
|
62,653
|
$
|
20,793
|
$
|
(16,757
|
)
|
$
|
61,434
|
$
|
128,123
|
|||||||||||||||
|
|
Nine Months Ended
September 30, 2026
|
|||||||||||||||||||||
|
|
Historical
|
Transaction Accounting
Adjustments
|
||||||||||||||||||||
|
|
Remix
|
Passage
|
Merger
Adjustments
|
Financing
Adjustments
|
Pro Forma
Combined
|
|||||||||||||||||
|
|
||||||||||||||||||||||
|
Collaboration revenue
|
$
|
46,164
|
$
|
-
|
$
|
-
|
$
|
46,164
|
||||||||||||||
|
Operating expenses:
|
||||||||||||||||||||||
|
Research and development
|
40,880
|
8,933
|
-
|
-
|
49,813
|
|||||||||||||||||
|
General and administrative
|
15,894
|
15,104
|
-
|
-
|
30,998
|
|||||||||||||||||
|
Net gain on lease termination
|
(2,577
|
)
|
-
|
-
|
(2,577
|
)
|
||||||||||||||||
|
Total operating expenses
|
56,774
|
21,460
|
-
|
-
|
78,234
|
|||||||||||||||||
|
Loss from operations
|
(10,610
|
)
|
(21,460
|
)
|
-
|
-
|
(32,070
|
)
|
||||||||||||||
|
Other (expense) income:
|
||||||||||||||||||||||
|
Change in fair value of convertible notes payable and warrant liabilities, related party
|
(4,280
|
)
|
4,780
|
N
|
-
|
500
|
||||||||||||||||
|
Interest income
|
473
|
-
|
-
|
473
|
||||||||||||||||||
|
Other (expense) income, net
|
(21
|
)
|
1,361
|
-
|
-
|
1,340
|
||||||||||||||||
|
Total other (expense) income, net
|
(3,828
|
)
|
1,361
|
4,780
|
-
|
2,313
|
||||||||||||||||
|
|
||||||||||||||||||||||
|
Loss before income taxes
|
(14,438
|
)
|
(20,099
|
)
|
4,780
|
-
|
(29,757
|
)
|
||||||||||||||
|
Income tax expense
|
-
|
-
|
-
|
|||||||||||||||||||
|
Net loss
|
$
|
(14,438
|
)
|
$
|
(20,099
|
)
|
$
|
4,780
|
$
|
-
|
$
|
(29,757
|
)
|
|||||||||
|
|
||||||||||||||||||||||
|
Deemed contribution related to preferred stock exchange
|
30,970
|
|||||||||||||||||||||
|
Less: Earnings allocated to participating preferred securities
|
(16,319
|
)
|
||||||||||||||||||||
|
Net income (loss) attributable to common stockholders
|
$
|
213
|
||||||||||||||||||||
|
|
||||||||||||||||||||||
|
Weighted-average common shares outstanding — basic
|
7,918,093
|
3,210,850
|
7,162,383
|
|||||||||||||||||||
|
Weighted-average common shares outstanding — diluted
|
51,127,610
|
3,210,850
|
7,162,383
|
|||||||||||||||||||
|
|
||||||||||||||||||||||
|
Net income (loss) per share of common stock — basic
|
$
|
0.03
|
$
|
(6.26
|
)
|
$
|
(4.15
|
)
|
||||||||||||||
|
Net income (loss) per share of common stock — diluted
|
$
|
(0.42
|
)
|
$
|
(6.26
|
)
|
$
|
(4.15
|
)
|
|||||||||||||
|
|
Year Ended December 31,
2025
|
|||||||||||||||||||||
|
|
Historical
|
Transaction Accounting
Adjustments
|
||||||||||||||||||||
|
|
Remix
|
Passage
|
Merger
Adjustments
|
Financing
Adjustments
|
Pro Forma
Combined
|
|||||||||||||||||
|
|
||||||||||||||||||||||
|
Collaboration revenue
|
$
|
3,310
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
3,310
|
||||||||||||
|
Operating expenses:
|
||||||||||||||||||||||
|
Research and development
|
52,593
|
23,276
|
-
|
-
|
75,869
|
|||||||||||||||||
|
General and administrative
|
15,056
|
19,875
|
1,437
|
M
|
-
|
36,368
|
||||||||||||||||
|
Impairment of long-lived assets
|
-
|
6,145
|
-
|
-
|
6,145
|
|||||||||||||||||
|
Total operating expenses
|
67,649
|
49,296
|
1,437
|
-
|
118,382
|
|||||||||||||||||
|
Loss from operations
|
(64,339
|
)
|
(49,296
|
)
|
(1,437
|
)
|
-
|
(115,072
|
)
|
|||||||||||||
|
Other (expense) income:
|
||||||||||||||||||||||
|
Change in fair value of convertible notes payable and warrant liabilities, related party
|
(10,814
|
)
|
-
|
2,150
|
N
|
-
|
(8,664
|
)
|
||||||||||||||
|
Interest income
|
1,293
|
-
|
-
|
-
|
1,293
|
|||||||||||||||||
|
Other (expense) income, net
|
(27
|
)
|
3,774
|
-
|
-
|
3,747
|
||||||||||||||||
|
Total other (expense) income, net
|
(9,548
|
)
|
3,774
|
2,150
|
-
|
(3,624
|
)
|
|||||||||||||||
|
|
||||||||||||||||||||||
|
Loss before income taxes
|
(73,887
|
)
|
(45,522
|
)
|
713
|
-
|
(118,696
|
)
|
||||||||||||||
|
Income tax benefit
|
182
|
-
|
-
|
-
|
182
|
|||||||||||||||||
|
Net loss
|
$
|
(73,705
|
)
|
$
|
(45,522
|
)
|
$
|
713
|
$
|
-
|
$
|
(118,514
|
)
|
|||||||||
|
Deemed contribution recognized in connection with Exchange Agreements
|
30,970
|
|||||||||||||||||||||
|
Net loss attributable to common stockholders
|
$
|
(87,544
|
)
|
|||||||||||||||||||
|
|
||||||||||||||||||||||
|
Net loss per share of common stock, basic and diluted
|
$
|
(9.57
|
)
|
$
|
(14.35
|
)
|
$
|
(12.24
|
)
|
|||||||||||||
|
Weighted-average common shares outstanding, basic and diluted
|
7,700,621
|
3,172,870
|
7,149,765
|
|||||||||||||||||||
| 1. |
Description of the Merger and Related Transactions
|
|
Estimated shares of Passage Bio Common Stock to be owned by pre-Closing Passage Bio stockholders (i)
|
538,802
|
|||
|
Estimated Passage Bio equity awards outstanding upon Closing (ii)
|
81,504
|
|||
|
Estimated total shares of Passage Bio Common Stock outstanding immediately following the Closing attributable to
pre-Closing Passage Bio stockholders and holders of Passage Bio equity awards
|
620,306
|
|||
|
Estimated price per share of Passage Bio common stock (iii)
|
$
|
24.78
|
||
|
Estimated aggregate consideration deemed transferred
|
$
|
15,371
|
| (i) |
Reflects the estimated number of shares of Passage Bio Common Stock attributable to pre-Closing Passage Bio stockholders, before giving effect to the Reverse Stock Split.
|
| (ii) |
Reflects the estimated number of shares underlying outstanding Passage Bio equity awards expected to vest upon Closing. Such awards are included in the calculation of estimated
aggregate consideration deemed transferred.
|
| (iii) |
Reflects the assumed price per share of Passage Bio Common Stock, based on its closing market price as of November 16, 2026.
|
| 2. |
Basis of Presentation
|
| • |
Remix equity holders hold a substantial majority of the voting interests in the Combined Company;
|
| • |
Remix designees comprise a majority of the board of directors;
|
| • |
Remix’s senior management comprises the senior management of the Combined Company;
|
| • |
Remix’s business is the ongoing business of the Combined Company; and
|
| • |
Passage Bio’s pre-combination assets consist primarily of cash and other non-operating assets.
|
| 3. |
Shares of Passage Bio Common Stock and Pre-Funded Warrants Issued in Connection with the Merger and Concurrent Financing
|
|
Shares of Remix common stock outstanding
|
5,525,130
|
|||
|
Shares of Remix common stock issued upon conversion of Remix preferred stock
|
33,026,156
|
|||
|
Shares of Remix common stock issued upon conversion of the 2025 Convertible Notes
|
8,350,230
|
|||
|
Shares of Remix common stock issued upon net exercise of the 2025 Warrants
|
482,107
|
|||
|
Shares of Remix common stock issuable upon exercise of Remix pre-funded warrants issued pursuant to the Exchange
Agreements
|
109,181,447
|
|||
|
Estimated total Remix fully diluted shares immediately prior to the Closing
(excluding shares issued in the Concurrent Financing)
|
156,565,070
|
|||
|
Estimated Merger Exchange Ratio
|
0.0289
|
|||
|
Estimated fully diluted shares attributable to Remix Stockholders in the Merger
(excluding shares issued as a result of the Concurrent Financing)
|
4,526,259
|
|||
|
Shares of Remix common stock issued in the Subscription Financing
|
36,134,410
|
|||
|
Shares of Remix common stock issued upon conversion of the 2026 Bridge Notes
|
4,317,975
|
|||
|
Shares of Remix common stock issuable upon exercise of Remix pre-funded warrants issued in the Concurrent Financing
|
32,382,990
|
|||
|
Estimated total Remix fully diluted shares issued in the Concurrent Financing
|
72,835,375
|
|||
|
Estimated Concurrent Financing Exchange Ratio
|
0.0291
|
|||
|
Estimated fully diluted shares attributable to the Concurrent Financing
|
2,116,032
|
|||
|
Estimated total fully diluted shares attributable to Remix stockholders and Concurrent Financing
investors
|
6,642,291
|
| 4. |
Pro Forma Adjustments
|
| A. |
Reflects the net cash proceeds of approximately $65.2 million from the Subscription Financing, consisting of gross proceeds of $70.0 million less estimated issuance costs of
$4.8 million. Additionally, reflects the removal of $3.8 million of deferred financing costs recorded in prepaid expenses and other current assets and related amounts in accounts payable and accrued expenses as of September 30, 2026.
Securities issued in the Subscription Financing consist of shares of Remix common stock and pre-funded warrants to purchase Remix common stock. The common shares will convert into shares of Passage Bio Common Stock, and the pre-funded
warrants will become exercisable for Passage Bio Common Stock. Accordingly, the proceeds will be reflected in Passage Bio Common Stock at par value, to the extent attributable to shares issued, with the remainder reflected in additional
paid-in capital, including amounts attributable to equity-classified pre-funded warrants.
|
| B. |
Reflects the conversion or exchange of Remix’s 2026 Bridge Notes in connection with the Mergers. To the extent not exchanged pursuant to the Exchange Agreements, the 2026
Bridge Notes will convert into shares of Remix common stock, which immediately will convert into Passage Bio Common Stock. To the extent exchanged pursuant to the Exchange Agreements, the 2026 Bridge Notes will be surrendered and exchanged
for pre-funded warrants to purchase Remix common stock, which will be exercisable for Passage Bio Common Stock. The 2026 Bridge Notes will be carried at fair value and their carrying value of $30.1 million as of September 30, 2026 will be
reclassified to Passage Bio Common Stock (par value) to the extent attributable to shares issued, with the remainder reflected in additional paid-in capital, including amounts attributable to the equity-classified pre-funded warrants. The
adjustment also reflects the cash settlement of $2.0 million financing costs upon consummation of the Mergers, including $0.6 million previously accrued in accounts payable.
|
| C. |
Reflects the cash settlement of approximately $5.1 million of Passage Bio transaction costs incurred in connection with the Mergers that were not recognized in the historical
financial statements. Because Remix is the accounting acquirer, Passage Bio’s transaction costs are not treated as costs of the equity transaction. Consistent with reverse recapitalization accounting, these costs are reflected as a
reduction of cash and corresponding increase to accumulated deficit in the unaudited pro forma condensed combined balance sheet, with no related adjustment to the pro forma statements of operations.
|
| D. |
Reflects the cash settlement of approximately $10.6 million of Remix transaction costs incurred in connection with the Mergers, including $1.0 million related to a prepaid
directors’ and officers’ insurance policy, which is recorded as a prepaid expense in the unaudited pro forma condensed combined balance sheet. The remaining $9.6 million represents Remix’s transaction costs, which, consistent with reverse
recapitalization accounting, are recorded as a reduction of additional paid-in capital to the extent of cash received from Passage Bio, with any excess recognized as expense.
|
| E. |
Reflects the removal of Passage Bio’s nonrefundable sublicense and transition-services payment accrual, as the remaining obligations thereunder are nominal and do not represent
an obligation of the Combined Company. The offset is recorded in additional paid-in capital.
|
| F. |
Reflects the conversion or exchange of Remix’s 2025 Convertible Notes in connection with the Mergers. The 2025 Convertible Notes, which are carried at fair value, had a
carrying value of $38.5 million as of September 30, 2026. The adjustment reflects the derecognition of the notes, with the corresponding amounts recorded in Passage Bio Common Stock at par value, to the extent attributable to shares issued,
and additional paid-in capital, including amounts attributable to equity-classified pre-funded warrants.
|
| G. |
Reflects the termination of the 2023 Warrants in connection with the Merger in accordance with their terms. This adjustment reflects the derecognition of the warrant liability
of $0.4 million as of September 30, 2026, with the offset recorded in additional paid-in capital. The related historical change in fair value is eliminated (see Adjustment N).
|
| H. |
Reflects the exchange or net exercise of the 2025 Warrants in connection with the Mergers. Certain of the 2025 Warrants will be exchanged pursuant to the Exchange Agreements
for pre-funded warrants to purchase Remix common stock, which will become exercisable for Passage Bio Common Stock. The remaining 2025 Warrants will be net exercised for shares of Remix common stock, which will convert into Passage Bio
Common Stock. The $1.6 million historical 2025 Warrant liability will be reclassified to Passage Bio Common Stock at par value, to the extent attributable to shares issued, and additional paid-in capital, including amounts attributable to
equity-classified pre-funded warrants. No cash will be received upon net exercise, and the related historical change in fair value will be eliminated (see Adjustment N).
|
| I. |
Reflects the recapitalization of Remix’s historical equity in connection with the Mergers based on the Merger Exchange Ratio, as described below. The conversion or exchange is
reflected in Passage Bio Common Stock at par value, to the extent attributable to shares issued, and additional paid-in capital. The exchange of Remix’s historical pre-funded warrant liabilities for equity is described in Adjustment L.
|
| a. |
Reflects the conversion of the remaining outstanding shares of Remix Series Seed, Series A and Series B preferred stock into shares of Remix common stock, which will
immediately convert into shares of Passage Bio Common Stock. The historical carrying value of the preferred stock is reflected in Passage Bio Common Stock at par value, to the extent attributable to shares issued, and additional paid-in
capital.
|
| b. |
Reflects the conversion or exchange of outstanding shares of Remix common stock, excluding shares issued in the Concurrent Financing and shares addressed in Adjustments A, B, F
and H. Shares not exchanged under the Exchange Agreements will convert into Passage Bio Common Stock in the Mergers, while shares exchanged pursuant to the Exchange Agreements will be surrendered for equity-classified pre-funded warrants.
Accordingly, the adjustment will be reflected in Passage Bio Common Stock at par value, to the extent attributable to shares issued, and additional paid-in capital.
|
| J. |
Reflects the elimination of Passage Bio’s historical equity balances in connection with the reverse recapitalization. Because Passage Bio is the accounting acquiree, its
historical equity balances are not carried forward, and its accumulated deficit of $724.9 million as of September 30, 2026 is eliminated against additional paid-in capital.
|
| K. |
Reflects the charge to additional paid-in capital and accumulated deficit related to approximately $1.4 million of stock-based compensation expense associated with the Mergers,
consisting of: (a) $1.2 million of expense related to acceleration of unvested stock options pursuant to pre-existing grant agreements that provide for acceleration upon a change in control; and (b) $0.2 million of incremental expense
related to extension of exercise periods or other modifications of certain stock options. The related adjustment to the unaudited pro forma condensed combined statement of operations is described in Adjustment M.
|
| L. |
Reflects derecognition of $116.1 million of pre-funded warrant liabilities related to Remix’s Series Seed, Series A and Series B prefunded preferred stock warrant liabilities
as of September 30, 2026. The liabilities are derecognized upon exchange for equity, with the offset recorded in additional paid-in capital. No cash proceeds are received upon exchange.
|
| M. |
Reflects nonrecurring stock-based compensation expense of approximately $1.4 million associated with the Mergers, consisting of: (a) $1.2 million of expense from acceleration
of certain unvested stock options pursuant to pre-existing award agreements that provide for acceleration upon a change in control; and (b) $0.2 million of incremental expense related to extension of exercise periods or other modifications
of certain stock options. The affected employees are classified in general and administrative functions; accordingly, the charge is recorded in general and administrative expense in the unaudited pro forma condensed combined statement of
operations for the year ended December 31, 2025. The acceleration arises under the original terms of the awards and is not accounted for as a modification. The exercise-period extensions are accounted for as modifications under ASC 718,
with incremental fair value recognized immediately because the affected awards are fully vested.
|
| N. |
Reflects the elimination of changes in fair value recognized in Remix’s historical statements of operations related to the 2023 Warrants, 2025 Warrants 2025 Convertible Notes
and 2026 Convertible Notes. Because these instruments are assumed to have been terminated, net exercised, exchanged or converted, as applicable, as of January 1, 2025, the related fair-value remeasurements recognized in Remix’s historical
results are eliminated for the periods presented, as follows (in thousands):
|
|
Year Ended
December 31,
2025
|
Nine Months
Ended
September 30,
2026
|
|||||||
|
Change in fair value - 2026 Notes
|
100
|
|||||||
|
Change in fair value - 2025 convertible notes
|
$
|
-
|
$
|
11,900
|
||||
|
Change in fair value - 2025 Warrants
|
-
|
(1,288
|
)
|
|||||
|
Change in fair value - 2023 Warrants
|
2,150
|
(5,932
|
)
|
|||||
|
Total pro forma adjustment
|
$
|
2,150
|
$
|
4,780
|
||||
| 5. |
Pro Forma Loss per Share
|
|
|
Year Ended
December 31,
2025
|
Nine Months
Ended September
30, 2026
|
||||||
|
Numerator:
|
||||||||
|
Pro forma net loss
|
$
|
(118,514
|
)
|
$
|
(29,757
|
)
|
||
|
Deemed contribution recognized in connection with Exchange Agreements
|
30,970
|
-
|
||||||
|
Pro forma net loss attributable to common stockholders
|
(87,544
|
)
|
(29,757
|
)
|
||||
|
|
||||||||
|
Denominator:
|
||||||||
|
Weighted-average Remix common shares outstanding - basic and diluted (i)
|
4,700,621
|
4,918,093
|
||||||
|
Shares of Remix common stock issued upon conversion of Remix preferred stock
|
33,026,156
|
33,026,156
|
||||||
|
Shares of Remix common stock issued upon conversion of the 2025 Convertible Notes
|
8,350,230
|
8,350,230
|
||||||
|
Shares of Remix common stock issued upon net exercise of the 2025 Warrants
|
482,107
|
482,107
|
||||||
|
Shares of Remix common stock issuable upon exercise of Remix pre-funded warrants
|
109,181,447
|
109,181,447
|
||||||
|
Total
|
155,740,561
|
155,958,033
|
||||||
|
Estimated Merger Exchange Ratio
|
0.0289
|
0.0289
|
||||||
|
Estimated total shares of Passage Bio common stock issued to Remix Stockholders in the Merger
|
4,502,423
|
4,508,710
|
||||||
|
Shares of Remix common stock issued in the Subscription Financing
|
36,134,410
|
36,134,410
|
||||||
|
Shares of Remix common stock issued upon conversion of the 2026 Bridge Notes
|
4,317,975
|
4,317,975
|
||||||
|
Shares of Remix common stock issuable upon exercise of Remix pre-funded warrants issued in the Concurrent Financing
|
32,382,990
|
32,382,990
|
||||||
|
Total
|
72,835,375
|
72,835,375
|
||||||
|
Estimated Concurrent Financing Exchange Ratio
|
0.0291
|
0.0291
|
||||||
|
Estimated total shares of Passage Bio common stock issued to Remix Stockholders as a result of the
Concurrent Financing
|
2,116,031
|
2,116,032
|
||||||
|
Shares of Passage common stock issued upon acceleration of RSUs
|
2,500
|
2,500
|
||||||
|
Weighted-average Passage common shares outstanding—basic and diluted
|
528,811
|
535,141
|
||||||
|
Pro forma combined weighted-average common shares outstanding —basic and diluted
|
7,149,765
|
7,162,383
|
||||||
|
|
||||||||
|
Pro forma loss per share - basic and diluted
|
$
|
(12.24
|
)
|
$
|
(4.15
|
)
|
||
| (i) |
Excludes approximately 3.0 million Remix common shares that were exchanged for pre-funded warrants pursuant to the Exchange Agreements and therefore are excluded from
weighted-average Remix common shares outstanding for both periods presented. The shares underlying the related pre-funded warrants are included in the shares of Remix common stock issuable upon exercise of pre-funded warrants.
|